Detail of the clinical trial

Title of the trial A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
EudraCT number 2014-001617-12
Protocol number AP24534-14-203
Sponsor ARIAD Pharmaceuticals, Inc., (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited), 40 Landsdowne Street, Cambridge, MA 02139 , United States of America
Indications Hemato-oncology
Diagnosis Chronic Myeloid Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2015
Date of approval by Institute (SÚKL) 5.10.2015
Date of approval by EC 24.8.2015
Date of initiation CT in ČR
Date of ending CT in ČR 18.7.2018
Notice
Sites Fakultní nemocnice Olomouc,,I.P. Pavlova 6,Olomouc,775 20

‹‹ Back to list